Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 20, 2014, 05:11:01 AM

Login with username, password and session length


Members
  • Total Members: 23730
  • Latest: lume
Stats
  • Total Posts: 642739
  • Total Topics: 48891
  • Online Today: 183
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 5
Guests: 137
Total: 142

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Studies begin to identify genes linked to metabolic and body fat changes  (Read 1312 times)

0 Members and 1 Guest are viewing this topic.

Offline Ihavehope

  • Member
  • Posts: 1,366
  • Yes, I'm a cry baby, AND WHAT?
Findings from Denver

Three of the studies examined the effects of variation in the genes for apolipoproteins. These compounds are involved in the transport of cholesterol and other materials around the body, with variation in their genes having been linked to hardening of the arteries and blood triglyceride levels.

In one of these studies, investigators focused on six points within the apolipoprotein genes, two in gene E, three in gene C and one in gene A. In a cohort of 370 patients enrolled in a trial comparing ritonavir-boosted lopinavir (Kaletra) with nelfinavir (Viracept), the investigators found that the type of E genes a patient had were associated with changes in blood cholesterol levels. In contrast, variation at one point in the C gene determined the degree to which triglyceride levels rose (Gometz 2006).

The second study examined a range of genes suspected of being involved in determining blood fat levels, which included the apolipoprotein genes. The investigators concluded that patients with a set of particular variants in these genes were linked to higher triglyceride levels in response to ritonavir (Norvir) treatment. However, they also detected a set of genes that was linked to higher levels of high-density lipoprotein (HDL or ‘good’) cholesterol in patients taking non-nucleoside reverse transcriptase inhibitor-based treatment (Arnedo 2006).

Thirdly, Cossarizza et al. found evidence of a link between variation in the apolipoprotein C gene and the risk of the loss of fat from under the skin, due to a possible effect of the gene on the metabolism and death of fat cells or ‘adipocytes’.

This group also confirmed a previously-observed link between variations in the gene FAS-670 and fat loss.

In further study presented in Denver, Ranade et al. examined 285 sites within 137 genes for links with metabolic changes, as part of a larger study comparing various protease inhibitor- and NNRTI-containing HIV treatment regimens. In an analysis of 189 patients, only one of these genetic variations was identified as being linked to changes in blood fat levels, regardless of the patients’ race.

They found that a single variation in the gene for resistin, a hormone released by fat tissue, was linked to the risk of a patient developing elevated blood triglyceride levels or changes in blood cholesterol, as well as changes in resistance to insulin, a marker of the development of diabetes.

Finally, an Italian study found a link between variation in the multidrug resistance-1 (MDR-1) gene. This gene, which is better known through its link with resistance to various drugs including some HIV medications, was found to have a link with the accumulation of fat around the internal organs in patients on HIV therapy, as well as cholesterol levels. While patients with two identical copies of the gene, which produces poly-glycoprotein, were at a reduced risk of fat accumulation, patients with genes that differed at the same point were at an increased risk of developing high triglyceride levels (De Luca 2006).

Infected: April 2005
12/6/06 - Diagnosed HIV positive
12/19/06 - CD4 = 240  22% VL = 26,300
1/4/07 - CD4 = 200 16% VL = ?
2/9/07 = Started Kaletra/Truvada
3/13/07 = CD4 = 386 22% VL ?

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.